Literature DB >> 23160780

Lifestyle factors, autoimmune disease and family history in prognosis of non-hodgkin lymphoma overall and subtypes.

Julia F Simard1, Fredrik Baecklund, Ellen T Chang, Eva Baecklund, Henrik Hjalgrim, Hans -Olov Adami, Bengt Glimelius, Karin E Smedby.   

Abstract

Lifestyle factors and medical history are known to influence risk of non-Hodgkin lymphoma (NHL). Whether these factors affect the prognosis of NHL, especially its subtypes, is unclear. To investigate this, the association between these factors and all-cause and lymphoma-related mortality was assessed in a population-based cohort of 1,523 Swedish NHL patients included in the Scandinavian Lymphoma Etiology study in 1999-2002. Participants contributed time from NHL diagnosis until death or October 1, 2010, with virtually complete follow-up through linkage to the Swedish Cause of Death Register. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using stratified and multivariable-adjusted Cox regression models. During a median follow-up of 8.8 years, 670 patients (44%) died, with the majority of deaths attributed to lymphoma (86%). Current versus never smoking at diagnosis was associated with increased rate of all-cause death for all NHL (HR = 1.5, 1.2-1.8) and diffuse large B-cell lymphoma (HR = 1.8, 1.2-2.7). Low educational level (HR = 1.3, 1.1-1.7, <9 vs. >12 years) and NHL risk-associated autoimmune disease (HR = 1.4, 1.0-1.8) were associated with death for all NHL combined. However, evidence of an association with lymphoma-related death was limited. Body mass index, recent sunbathing and family history of hematopoietic malignancy were not consistently associated with death after NHL or its specific subtypes. These results add to the evidence that cigarette smoking, socioeconomic status and certain autoimmune diseases affect survival after NHL. Further investigations are needed to determine how these factors should be incorporated into clinical prognostic assessment.
Copyright © 2012 UICC.

Entities:  

Mesh:

Year:  2012        PMID: 23160780     DOI: 10.1002/ijc.27944

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

Review 1.  New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy.

Authors:  Dai Chihara; Loretta J Nastoupil; Jessica N Williams; Paul Lee; Jean L Koff; Christopher R Flowers
Journal:  Expert Rev Anticancer Ther       Date:  2015-04-11       Impact factor: 4.512

2.  Obesity and non-Hodgkin lymphoma survival in an ethnically diverse population: the Multiethnic Cohort study.

Authors:  Qi Jie Nicholas Leo; Nicholas J Ollberding; Lynne R Wilkens; Laurence N Kolonel; Brian E Henderson; Loic Le Marchand; Gertraud Maskarinec
Journal:  Cancer Causes Control       Date:  2014-07-29       Impact factor: 2.506

3.  Changes of T-lymphocyte subpopulation and differential expression pattern of the T-bet and GATA-3 genes in diffuse large B-cell lymphoma patients after chemotherapy.

Authors:  Qingsong Yin; Lin Chen; Qianyu Li; Ruihua Mi; Yufu Li; Xudong Wei; Yongping Song
Journal:  Cancer Cell Int       Date:  2014-12-24       Impact factor: 5.722

4.  The care center influences the management of lymphoma patients in a universal health care system: an observational cohort study.

Authors:  S Lamy; C Bettiol; P Grosclaude; G Compaci; G Albertus; C Récher; J C Nogaro; F Despas; G Laurent; C Delpierre
Journal:  BMC Health Serv Res       Date:  2016-08-02       Impact factor: 2.655

5.  History of autoimmune conditions and lymphoma prognosis.

Authors:  Geffen Kleinstern; Matthew J Maurer; Mark Liebow; Thomas M Habermann; Jean L Koff; Cristine Allmer; Thomas E Witzig; Grzegorz S Nowakowski; Ivana N Micallef; Patrick B Johnston; David J Inwards; Carrie A Thompson; Andrew L Feldman; Brian K Link; Christopher Flowers; Susan L Slager; James R Cerhan
Journal:  Blood Cancer J       Date:  2018-08-01       Impact factor: 11.037

6.  The prognostic effect of smoking status on intensively treated acute myeloid leukaemia - A Danish nationwide cohort study.

Authors:  Daniel Kristensen; Lars B Nielsen; Anne S Roug; Tove-Christina C Kristensen; Tarec C El-Galaly; Jan M Nørgaard; Claus W Marcher; Claudia Schöllkopf; Kim Theilgaard-Mönch; Marianne T Severinsen
Journal:  Br J Haematol       Date:  2020-04-21       Impact factor: 6.998

7.  A French multicentric prospective prognostic cohort with epidemiological, clinical, biological and treatment information to improve knowledge on lymphoma patients: study protocol of the "REal world dAta in LYmphoma and survival in adults" (REALYSA) cohort.

Authors:  Hervé Ghesquières; Cédric Rossi; Fanny Cherblanc; Sandra Le Guyader-Peyrou; Fontanet Bijou; Pierre Sujobert; Pascale Fabbro-Peray; Adeline Bernier; Aurélien Belot; Loic Chartier; Luc-Matthieu Fornecker; Isabelle Baldi; Krimo Bouabdallah; Camille Laurent; Lucie Oberic; Nadine Morineau; Steven Le Gouill; Franck Morschhauser; Corinne Haioun; Gandhi Damaj; Stéphanie Guidez; Gaëlle Labouré; Olivier Fitoussi; Laure Lebras; Rémy Gressin; Gilles Salles; Loïc Ysebaert; Alain Monnereau
Journal:  BMC Public Health       Date:  2021-03-02       Impact factor: 3.295

8.  Body mass index and survival of patients with lymphoma.

Authors:  Dai Chihara; Melissa C Larson; Dennis P Robinson; Carrie A Thompson; Matthew J Maurer; Carla Casulo; Priyanka Pophali; Brian K Link; Thomas M Habermann; Andrew L Feldman; Christopher R Flowers; James R Cerhan; Lindsay M Morton
Journal:  Leuk Lymphoma       Date:  2021-06-14

9.  Occupational ultraviolet exposure and risk of non-Hodgkin's lymphomas: a meta-analysis.

Authors:  Demin Lu; Fei Xu; Kaiming Hu; Li Yin; Huijie Duan; Jiaojiao Zhang; SuZhan Zhang
Journal:  Oncotarget       Date:  2017-05-24

10.  Concordance in survival among first-degree relatives diagnosed with indolent lymphoid malignancies including chronic lymphocytic leukemia.

Authors:  Fredrik Baecklund; Sara Ekberg; Richard Rosenquist; Johan Askling; Sandra Eloranta; Karin E Smedby
Journal:  Eur J Haematol       Date:  2020-09-29       Impact factor: 2.997

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.